$ACET
Adicet Bio, Inc.

2021 Q4 Form 10-K Financial Statement

#000095017022003753 Filed on March 15, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q1 2021
Revenue $5.468M -$3.980M $9.730M
YoY Change 1.07% -45.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.352M $5.630M $22.22M
YoY Change 25.04% 121.65% -2.37%
% of Gross Profit
Research & Development $13.46M $11.74M $48.94M
YoY Change 39.03% 66.97% 42.55%
% of Gross Profit
Depreciation & Amortization $365.0K $330.0K $1.538M
YoY Change 14.06% 1000.0% 25.04%
% of Gross Profit
Operating Expenses $19.81M $17.37M $71.16M
YoY Change 34.21% 81.78% 24.64%
Operating Profit -$21.35M -$61.43M
YoY Change 56.75%
Interest Expense $12.00K $50.00K $176.0K
YoY Change -60.0% 31.34%
% of Operating Profit
Other Income/Expense, Net -$294.0K -$4.000K -$606.0K
YoY Change -233.64% -105.71% -36.41%
Pretax Income -$15.82M -$21.37M -$62.12M
YoY Change 73.89% 198.21% 57.3%
Income Tax -$11.00K -$48.00K -$125.0K
% Of Pretax Income
Net Earnings -$15.81M -$21.32M -$62.00M
YoY Change 76.48% 375.23% 69.04%
Net Earnings / Revenue -289.19% -637.19%
Basic Earnings Per Share -$0.82 -$2.00
Diluted Earnings Per Share -$465.8K -$0.82 -$2.003M
COMMON SHARES
Basic Shares Outstanding 31.96M 26.10M 30.95M
Diluted Shares Outstanding 26.10M 30.95M

Balance Sheet

Concept 2021 Q4 2021 Q1 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $277.5M $223.4M $277.5M
YoY Change 193.34% 192.82% 193.39%
Cash & Equivalents $277.5M $221.7M $277.5M
Short-Term Investments $0.00 $1.753M $0.00
Other Short-Term Assets $31.00K $124.0K $4.680M
YoY Change -86.46% -89.67% 56.0%
Inventory
Prepaid Expenses $115.0K $1.732M
Receivables $185.0K $185.0K
Other Receivables $29.00K $29.00K
Total Short-Term Assets $282.4M $229.1M $282.4M
YoY Change 181.49% 195.23% 181.59%
LONG-TERM ASSETS
Property, Plant & Equipment $14.64M $3.122M $35.00M
YoY Change 424.84% 680.5% 35.14%
Goodwill $19.46M $19.86M
YoY Change -3.12%
Intangibles $0.00
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change
Other Assets $1.887M $2.099M $2.037M
YoY Change 2.72% 949.5% -68.17%
Total Long-Term Assets $56.50M $52.97M $56.50M
YoY Change 5.61% 8728.83% 5.61%
TOTAL ASSETS
Total Short-Term Assets $282.4M $229.1M $282.4M
Total Long-Term Assets $56.50M $52.97M $56.50M
Total Assets $338.9M $282.1M $338.9M
YoY Change 120.33% 260.71% 120.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.263M $1.748M $3.263M
YoY Change 110.24% 45.67% 103.94%
Accrued Expenses $8.249M $5.500M $8.249M
YoY Change 19.55% 292.86% 19.55%
Deferred Revenue $4.805M $17.96M
YoY Change -65.63%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.32M $25.18M $16.32M
YoY Change -27.41% 868.58% -27.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $115.0K $20.60M $19.49M
YoY Change -8.92%
Total Long-Term Liabilities $115.0K $20.60M $19.49M
YoY Change -8.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.32M $25.18M $16.32M
Total Long-Term Liabilities $115.0K $20.60M $19.49M
Total Liabilities $35.81M $45.81M $35.81M
YoY Change -18.63% 1662.08% -18.62%
SHAREHOLDERS EQUITY
Retained Earnings -$168.3M -$127.6M
YoY Change 58.31% -20.8%
Common Stock $471.5M $363.9M
YoY Change 118.14% 53.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $303.1M $236.3M $303.1M
YoY Change
Total Liabilities & Shareholders Equity $338.9M $282.1M $338.9M
YoY Change 120.33% 260.68% 120.38%

Cashflow Statement

Concept 2021 Q4 2021 Q1 2021
OPERATING ACTIVITIES
Net Income -$15.81M -$21.32M -$62.00M
YoY Change 76.48% 375.23% 69.04%
Depreciation, Depletion And Amortization $365.0K $330.0K $1.538M
YoY Change 14.06% 1000.0% 25.04%
Cash From Operating Activities -$13.44M -$15.15M -$51.05M
YoY Change 0.78% 81.35% 22.86%
INVESTING ACTIVITIES
Capital Expenditures -$3.078M $658.0K $13.05M
YoY Change 755.0% 1217.78%
Acquisitions
YoY Change
Other Investing Activities $0.00 $8.500M $10.25M
YoY Change -100.0% -80.0% -91.18%
Cash From Investing Activities -$3.078M $7.842M -$2.796M
YoY Change -124.72% 76.42% -102.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$128.8M $238.1M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 97.46M 144.9M 242.7M
YoY Change 37385.77% 344869.05% 79994.06%
NET CHANGE
Cash From Operating Activities -13.44M -15.15M -51.05M
Cash From Investing Activities -3.078M 7.842M -2.796M
Cash From Financing Activities 97.46M 144.9M 242.7M
Net Change In Cash 80.94M 137.6M 188.8M
YoY Change -12947.78% -3659.72% 155.3%
FREE CASH FLOW
Cash From Operating Activities -$13.44M -$15.15M -$51.05M
Capital Expenditures -$3.078M $658.0K $13.05M
Free Cash Flow -$10.37M -$15.80M -$64.10M
YoY Change -20.14% 89.22% 50.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2020Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2021 acet Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement
IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
CY2021 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001720580
CY2020 us-gaap Sublease Income
SubleaseIncome
CY2019 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
CY2020 acet Proceeds From Sales Of Marketable Debt Securities
ProceedsFromSalesOfMarketableDebtSecurities
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2021 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 acet Common Stock Offering Costs Included In Accrued Liabilities At Period End
CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd
CY2020Q4 us-gaap Other Liabilities
OtherLiabilities
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2021 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-11-30
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38359
CY2021 dei Entity Registrant Name
EntityRegistrantName
Adicet Bio, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3305277
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Clarendon Street
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Floor 6
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
CY2021 dei City Area Code
CityAreaCode
650
CY2021 dei Local Phone Number
LocalPhoneNumber
503-9095
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
ACET
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
226000000.0
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39877109
CY2021 dei Auditor Firm
AuditorFirmId
185
CY2021 dei Auditor Name
AuditorName
KPMG LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
277544000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84330000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10284000
CY2021Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
185000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4709000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5722000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
282438000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
100336000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14643000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2790000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20358000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23066000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
216126000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168324000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-106325000
CY2021Q4 us-gaap Goodwill
Goodwill
19462000
CY2020Q4 us-gaap Goodwill
Goodwill
20089000
CY2020Q4 us-gaap Development In Process
DevelopmentInProcess
1190000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4527000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1887000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1837000
CY2021Q4 us-gaap Assets
Assets
338938000
CY2020Q4 us-gaap Assets
Assets
153835000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3263000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1552000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4805000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13980000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6682000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5732000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1567000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1215000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16317000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22479000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19377000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20424000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
980000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
125000
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
115000
CY2021Q4 us-gaap Liabilities
Liabilities
35809000
CY2020Q4 us-gaap Liabilities
Liabilities
44008000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39736914
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39736914
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19677249
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19677249
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
471449000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
24000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4688000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
303129000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
109827000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
338938000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153835000
CY2021 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
9730000
CY2020 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
17903000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48943000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34334000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22220000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22760000
CY2021 us-gaap Operating Expenses
OperatingExpenses
71163000
CY2020 us-gaap Operating Expenses
OperatingExpenses
57094000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-61433000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-39191000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
91000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
785000
CY2021 us-gaap Interest Expense
InterestExpense
176000
CY2020 us-gaap Interest Expense
InterestExpense
134000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-606000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-953000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62124000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39493000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-125000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2815000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-61999000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36678000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.00
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.01
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30952152
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7319977
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2021 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-24000
CY2020 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
1000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62023000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36677000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-60366000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
460000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5263000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
114083000
CY2020 acet Stock Exchanged During Period Value In Connection With Merger
StockExchangedDuringPeriodValueInConnectionWithMerger
83516000
CY2020 acet Stock Issued During Period Value Upon Accelerated Vesting Of Rsu With Merger
StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger
626000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2922000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36678000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
109827000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
823940000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
237997000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
129000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12511000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-61999000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-24000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
303129000
CY2021 us-gaap Profit Loss
ProfitLoss
-61999000
CY2020 us-gaap Profit Loss
ProfitLoss
-36678000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1538000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1226000
CY2021 us-gaap Other Noncash Expense
OtherNoncashExpense
2529000
CY2020 us-gaap Other Noncash Expense
OtherNoncashExpense
725000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
12511000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
5263000
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-31000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-10000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-5000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
897000
CY2021 acet Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
1190000
CY2020 acet Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
2300000
CY2021 acet Gain On Remeasurement Of Contingent Consideration Liability
GainOnRemeasurementOfContingentConsiderationLiability
-980000
CY2020 acet Gain On Remeasurement Of Contingent Consideration Liability
GainOnRemeasurementOfContingentConsiderationLiability
-1900000
CY2021 acet Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
175000
CY2020 acet Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
134000
CY2021 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
30000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1634000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3233000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-42000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1260000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1137000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-814000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9175000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7903000
CY2021 acet Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-511000
CY2020 acet Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-859000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
855000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
787000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-9000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-242000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51052000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41552000
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
64114000
CY2021 acet Proceeds From Sales Of Marketable Debt Securities
ProceedsFromSalesOfMarketableDebtSecurities
7500000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5700000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2750000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
57793000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13046000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
990000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2796000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
115217000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
238129000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
129000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4688000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
460000
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
261000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
157000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
242685000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
303000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
188837000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
73968000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88857000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14889000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
277694000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88857000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
277544000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84330000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4527000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
277694000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88857000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
43000
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
3000
CY2021 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
2766000
CY2020 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
664000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
651000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
115000
CY2021 acet Common Stock Offering Costs Included In Accrued Liabilities At Period End
CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd
132000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22367000
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
114083000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2922000
CY2020 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
84142000
CY2021 acet Adjustment To Goodwill
AdjustmentToGoodwill
413000
CY2020 acet Adjustment To Goodwill
AdjustmentToGoodwill
650000
CY2020 acet Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement
IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement
144000
CY2021 acet Entity Date Of Merger
EntityDateOfMerger
2020-04-28
CY2021Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.25
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7
CY2020Q3 acet Exchange Ratio
ExchangeRatio
0.1240
CY2021Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.25
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of the intangible assets acquired in business combinations, redeemable convertible preferred stock warrant liability, redeemable convertible preferred stock tranche liability, the Technion Research and Development Foundation liability (TRDF Liability), contingent consideration liability for contingent value right (CVR), deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company’s incremental borrowing rate. Actual results could differ from those estimates.</span></p>
CY2021 acet Gain Loss On Change In Fair Value Of Contingent Consideration Liability
GainLossOnChangeInFairValueOfContingentConsiderationLiability
1000000.0
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, and marketable debt securities. The Company’s cash and cash equivalents are held at two financial institutions in the United States and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents and marketable debt securities in money market funds, United States government securities, commercial paper, corporate bonds, and asset-backed securities. The Company limits its credit risk associated with cash equivalents and marketable debt securities by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents and marketable debt securities to date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customer, Regeneron, which represents </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company’s total revenue during the years ended December 31, 2021 and 2020 and outstanding accounts receivable as of December 31, 2021 (see Note 10).</span></p>
CY2021Q4 acet Number Of Customer
NumberOfCustomer
1
CY2020 acet Customers Percentage Of Total Revenue
CustomersPercentageOfTotalRevenue
1
CY2021 acet Customers Percentage Of Total Revenue
CustomersPercentageOfTotalRevenue
1
CY2021Q4 srt Financing Receivable Nonaccrual To Outstanding Percent
FinancingReceivableNonaccrualToOutstandingPercent
1
CY2021Q1 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
500000
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
700000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P60D
CY2021 acet Increase In Construction In Progress
IncreaseInConstructionInProgress
11900000
CY2020 acet Increase In Construction In Progress
IncreaseInConstructionInProgress
11900000
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
2300000
CY2021Q4 acet Estimated Fair Value Of Cvr Liability
EstimatedFairValueOfCVRLiability
0
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10260000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
24000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10284000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10284000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
10284000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1884000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1443000
CY2021Q4 acet Prepayments To Cros
PrepaymentsToCros
1658000
CY2020Q4 acet Prepayments To Cros
PrepaymentsToCros
420000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1021000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
761000
CY2021Q4 acet Prepayments To Cmos
PrepaymentsToCmos
115000
CY2020Q4 acet Prepayments To Cmos
PrepaymentsToCmos
135000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
229000
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2711000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
29000
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
23000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4709000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5722000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20969000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7654000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6326000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4864000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14643000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2790000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1500000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1200000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4020000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3833000
CY2021Q4 acet Accrued Cmo Costs
AccruedCmoCosts
1077000
CY2020Q4 acet Accrued Cmo Costs
AccruedCmoCosts
244000
CY2021Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
546000
CY2020Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
363000
CY2021Q4 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
504000
CY2020Q4 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
65000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
503000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
272000
CY2021Q4 acet Accrued Cro Costs
AccruedCroCosts
32000
CY2020Q4 acet Accrued Cro Costs
AccruedCroCosts
955000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6682000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5732000
CY2020Q2 us-gaap Loans Receivable Basis Spread On Variable Rate
LoansReceivableBasisSpreadOnVariableRate
0.0500
CY2021 us-gaap Debt Instrument Maturity Date Range End1
DebtInstrumentMaturityDateRangeEnd1
2021-10-28
CY2021Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
100000
CY2021 acet Exercised Investment Right And Purchased
ExercisedInvestmentRightAndPurchased
10000000.0
CY2021 acet Licence Agreement Cumulative Revenue Recognised
LicenceAgreementCumulativeRevenueRecognised
40200000
CY2021 acet License And Collaboration Revenue
LicenseAndCollaborationRevenue
9200000
CY2020 acet License And Collaboration Revenue
LicenseAndCollaborationRevenue
17900000
CY2021 acet Increase Decrease In Lease Obligation
IncreaseDecreaseInLeaseObligation
0
CY2021Q2 acet Amended Lease Agreement Description
AmendedLeaseAgreementDescription
the Company entered into an amendment to the Menlo Park lease to extend the term of the lease from March 31, 2022 to June 30, 2022 and replace the previously leased premises (known as 173 and 175-177 Jefferson Drive) with another nearby premises (known as 235 Constitution Drive).
CY2021 acet Operating Leases Commencement Date
OperatingLeasesCommencementDate
2021-07-15
CY2021 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-06-30
CY2021Q4 acet Operating Leases Future Minimum Sublease Income Due Current
OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent
657000
CY2021Q4 acet Operating Leases Future Minimum Sublease Income Due In Two Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears
671000
CY2021Q4 acet Operating Leases Future Minimum Sublease Income Due In Three Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears
685000
CY2021Q4 acet Operating Leases Future Minimum Sublease Income Due In Four Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears
699000
CY2021Q4 acet Operating Leases Future Minimum Sublease Income Due In Five Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears
416000
CY2021Q4 acet Operating Leases Future Minimum Sublease Income Due
OperatingLeasesFutureMinimumSubleaseIncomeDue
3128000
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0720
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
4282000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
894000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
235000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
56000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2021 us-gaap Sublease Income
SubleaseIncome
223000
CY2021 us-gaap Lease Cost
LeaseCost
4294000
CY2020 us-gaap Lease Cost
LeaseCost
950000
CY2021 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
511000
CY2020 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
859000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22367000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20400000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
20900000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
2933000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
3428000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
3525000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
3625000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
13747000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
27258000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6314000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
20944000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1567000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19377000
CY2021 acet Lawsuits Filed Against Company
LawsuitsFiledAgainstCompany
7
CY2020Q4 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
200000
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
10575513
CY2021Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
13.00
CY2021Q1 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
128800000
CY2021Q1 us-gaap Sale Of Stock Description Of Transaction
SaleOfStockDescriptionOfTransaction
the Company also entered into a stock purchase agreement with certain existing investors to purchase 1,153,840 shares of our common stock for $15.0 million at a price per share equal to the public offering price, with an initial closing for investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.
CY2021Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1153840
CY2021Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
15000000.0
CY2021 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
7187500
CY2021Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
14.00
CY2021 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
94200000
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6829205
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5672757
CY2020Q4 acet Class Of Warrant Outstanding And Exercisable To Purchase Preferred Shares
ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares
226191
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.3177
CY2020 acet Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term
WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm
P5Y7M28D
CY2021 acet Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
0
CY2021 acet Class Of Warrant Exercised
ClassOfWarrantExercised
-5301
CY2021Q4 acet Class Of Warrant Outstanding And Exercisable To Purchase Common Stock
ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock
220890
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.3177
CY2021 acet Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term
WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm
P4Y7M28D
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
220890
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12511000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5263000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
560000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3706945
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.90
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M23D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15126000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2161472
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.37
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1125339
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.17
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
867761
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
14.06
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3875317
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13212000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
991847
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.42
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y5M15D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4033000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3875317
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y10M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
13212000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.772
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.798
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.726
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.963
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.001
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.001
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.017
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10100000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2500000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4100000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12511000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5263000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-61999000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36678000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30952152
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7319977
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.00
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.01
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4867867
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3933136
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-2678000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
105000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-2573000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-125000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-242000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-125000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-242000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-125000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2815000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.019
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.005
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.069
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.061
CY2021 acet Effective Income Tax Rate Reconciliation Nol Carryback
EffectiveIncomeTaxRateReconciliationNOLCarryback
0.000
CY2020 acet Effective Income Tax Rate Reconciliation Nol Carryback
EffectiveIncomeTaxRateReconciliationNOLCarryback
0.067
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.248
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.258
CY2021 acet Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And Trdf Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability
0.000
CY2020 acet Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And Trdf Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability
-0.005
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.010
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.001
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.071
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
67675000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
51796000
CY2021Q4 acet Deferred Tax Operating Lease Right Of Use Asset Liability
DeferredTaxOperatingLeaseRightOfUseAssetLiability
5504000
CY2020Q4 acet Deferred Tax Operating Lease Right Of Use Asset Liability
DeferredTaxOperatingLeaseRightOfUseAssetLiability
5686000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1263000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2857000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1726000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1750000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1081000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1195000
CY2021Q4 acet Deferred Tax Assets Fixed Assets
DeferredTaxAssetsFixedAssets
196000
CY2020Q4 acet Deferred Tax Assets Fixed Assets
DeferredTaxAssetsFixedAssets
0
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1042000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
654000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
26000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
26000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
78513000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
63964000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
73163000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57715000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
5350000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6249000
CY2021Q4 acet Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
0
CY2020Q4 acet Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
0
CY2021Q4 acet Deferred Tax Basis Difference Iprd
DeferredTaxBasisDifferenceIPRD
0
CY2020Q4 acet Deferred Tax Basis Difference Iprd
DeferredTaxBasisDifferenceIPRD
-313000
CY2021Q4 acet Deferred Tax Operating Lease Right Of Use Asset
DeferredTaxOperatingLeaseRightOfUseAsset
-5350000
CY2020Q4 acet Deferred Tax Operating Lease Right Of Use Asset
DeferredTaxOperatingLeaseRightOfUseAsset
-6061000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
125000
CY2021 acet Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
15500000
CY2020 acet Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
37900000
CY2020 acet Ownership Change Plan Description
OwnershipChangePlanDescription
In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
797000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
797000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
3243000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4040000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
797000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2020 acet Company Contribution To Plan With Respect To Employees Contribution
CompanyContributionToPlanWithRespectToEmployeesContribution
0

Files In Submission

Name View Source Status
R14.htm Edgar Link pending
0000950170-22-003753-index-headers.html Edgar Link pending
0000950170-22-003753-index.html Edgar Link pending
0000950170-22-003753.txt Edgar Link pending
0000950170-22-003753-xbrl.zip Edgar Link pending
acet-20211231.htm Edgar Link pending
acet-20211231.xsd Edgar Link pending
acet-20211231_cal.xml Edgar Link unprocessable
acet-20211231_def.xml Edgar Link unprocessable
acet-20211231_htm.xml Edgar Link completed
acet-20211231_lab.xml Edgar Link unprocessable
acet-20211231_pre.xml Edgar Link unprocessable
acet-ex10_11.htm Edgar Link pending
acet-ex10_14.htm Edgar Link pending
acet-ex10_15.htm Edgar Link pending
acet-ex10_16.htm Edgar Link pending
acet-ex10_17.htm Edgar Link pending
acet-ex10_18.htm Edgar Link pending
acet-ex10_19.htm Edgar Link pending
acet-ex23_1.htm Edgar Link pending
acet-ex31_1.htm Edgar Link pending
acet-ex31_2.htm Edgar Link pending
acet-ex32_1.htm Edgar Link pending
acet-ex4_3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img102984888_0.jpg Edgar Link pending
img102984888_1.jpg Edgar Link pending
img102984888_10.jpg Edgar Link pending
img102984888_11.jpg Edgar Link pending
img102984888_12.jpg Edgar Link pending
img102984888_13.jpg Edgar Link pending
img102984888_14.jpg Edgar Link pending
img102984888_15.jpg Edgar Link pending
img102984888_16.jpg Edgar Link pending
img102984888_17.jpg Edgar Link pending
img102984888_2.jpg Edgar Link pending
img102984888_3.jpg Edgar Link pending
img102984888_4.jpg Edgar Link pending
img102984888_5.jpg Edgar Link pending
img102984888_6.jpg Edgar Link pending
img102984888_7.jpg Edgar Link pending
img102984888_8.jpg Edgar Link pending
img102984888_9.jpg Edgar Link pending
img128415308_0.jpg Edgar Link pending
img128415308_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending